The EU Commission’s proposed EU Industrial Accelerator Act (IAA) has been welcomed by the European chemical industry association, Cefic, as having the potential to accelerate industrial decarbonisation and strengthen resilience and competitiveness. Cefic adds, however, that more is needed, particularly on the demand side, where public procurement provisions remain limited for the chemical sector.
Nigel P. Freestone from the University of Northampton discusses selected research papers from recent journal issues for Issue 4 2026 of C&I magazine.
A group in the US has created the first ever materials that can change colour and texture, inspired by nature. Octopus and cuttlefish are famed for their ability to change not just colour but texture to blend into their background.
US speciality and fine chemical volumes grew slightly by 0.2% to reach 3.52m t in January 2026, compared with a 0.8% drop in December 2025 and a 0.4% increase in November 2025. This also compares with a better-than-expected 0.4% growth in overall US industrial production in both November and December 2025.
Scientists have found a way to significantly boost ‘blue’ energy, which generates electricity from the mixing of saltwater and freshwater. They designed a prototype membrane made from nanopores coated with lipids, which allows selected ions to pass through efficiently.
Practical new nickel catalysts have been created for cross-coupled reactions. These reactions, crucial to industry, involve transition metal catalysts bringing together molecular fragments to build more complex molecules. The new nickel catalysts have been praised as a platform-level advance.
Expert scientists summarise some of their selected research papers from recent journal issues. Read the organic chemistry highlights from G. Richard Stephenson, University of East Anglia, UK in Issue 4 2026 of C&I magazine.
The Taiwanese government has unveiled a four-year national pharmaceutical resilience preparedness programme with a budget of NewTaiwan$24bn. The programme will focus on three areas: domestic production for domestic use, smart allocation, and international partnerships to comprehensively build Taiwan’s pharmaceutical supply, from source production to clinical use.